Demographics
| Variable . | Total subjects . |
|---|---|
| Male sex, n (%) | 40 (62.5) |
| Age at transplant (range), y | 5.5 (2.7-11.7) |
| Race, n (%) | |
| Caucasian | 51 (79.7) |
| African American | 7 (10.9) |
| Asian | 3 (4.7) |
| Mixed | 3 (4.7) |
| Diagnostic group, n (%) | |
| Malignancy | 18 (28.1) |
| Immune deficiency | 28 (43.8) |
| Marrow failure | 8 (12.5) |
| Benign hematology | 7 (10.9) |
| Genetic/metabolic | 3 (4.7) |
| Stem cell donor type, n (%) | |
| Related (MRD, MMRD, haplo) | 30 (46.9) |
| Unrelated (MUD, MMUD) | 26 (40.6) |
| Autologous | 8 (12.5) |
| Stem cell source, n (%) | |
| Bone marrow (BM) | 41 (64) |
| Peripheral blood (PBSC) | 19 (29.7) |
| Cord blood (Cord) | 4 (6.3) |
| HLA match (allo-HSCT only), n (%) | |
| Fully matched (MRD, MUD) | 30 (53.6) |
| Mismatched (MMR, MMUD, haplo) | 26 (46.4) |
| Conditioning regimen type, n (%) | |
| Myeloablative | 35 (54.7) |
| Reduced intensity | 29 (45.3) |
| GVHD prophylaxis (allo-HSCT only), n (%) | |
| Calcineurin inhibitors | 49 (87.5) |
| T-cell depletion | 7 (12.5) |
| Pretransplant cystatin C GFR (IQR), mL/min | 129 (110-143) |
| Pretransplant rUPCR (range), mg/mg | 0.4 (0.2-0.8) |
| Variable . | Total subjects . |
|---|---|
| Male sex, n (%) | 40 (62.5) |
| Age at transplant (range), y | 5.5 (2.7-11.7) |
| Race, n (%) | |
| Caucasian | 51 (79.7) |
| African American | 7 (10.9) |
| Asian | 3 (4.7) |
| Mixed | 3 (4.7) |
| Diagnostic group, n (%) | |
| Malignancy | 18 (28.1) |
| Immune deficiency | 28 (43.8) |
| Marrow failure | 8 (12.5) |
| Benign hematology | 7 (10.9) |
| Genetic/metabolic | 3 (4.7) |
| Stem cell donor type, n (%) | |
| Related (MRD, MMRD, haplo) | 30 (46.9) |
| Unrelated (MUD, MMUD) | 26 (40.6) |
| Autologous | 8 (12.5) |
| Stem cell source, n (%) | |
| Bone marrow (BM) | 41 (64) |
| Peripheral blood (PBSC) | 19 (29.7) |
| Cord blood (Cord) | 4 (6.3) |
| HLA match (allo-HSCT only), n (%) | |
| Fully matched (MRD, MUD) | 30 (53.6) |
| Mismatched (MMR, MMUD, haplo) | 26 (46.4) |
| Conditioning regimen type, n (%) | |
| Myeloablative | 35 (54.7) |
| Reduced intensity | 29 (45.3) |
| GVHD prophylaxis (allo-HSCT only), n (%) | |
| Calcineurin inhibitors | 49 (87.5) |
| T-cell depletion | 7 (12.5) |
| Pretransplant cystatin C GFR (IQR), mL/min | 129 (110-143) |
| Pretransplant rUPCR (range), mg/mg | 0.4 (0.2-0.8) |
MRD, matched related; MMRD, mismatched related; haplo: haploidentical; MUD, matched unrelated; MMUD, mismatched unrelated; BM, bone marrow.